TrialNature cancer2025

Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial).

Julia Maria Ressler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.